Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Alessandro Busca; Jon Salmanton-García; Francesco Marchesi; Francesca Farina; Guldane Cengiz Seval; Jaap Van Doesum; Nick De Jonge; Nathan C. Bahr; Johan Maertens; Joseph Meletiadis; Nicola S. Fracchiolla; Barbora Weinbergerová; Luisa Verga; Zdeněk Ráčil; Moraima Jiménez; Andreas Glenthøj; Ola Blennow; Alina Daniela Tanase; Martin Schönlein; Lucia Prezioso; Nina Khanna; Rafael F. Duarte; Pavel Žák; Marcio Nucci; Marina Machado; Austin Kulasekararaj; Ildefonso Espigado; Elizabeth De Kort; José-María Ribera-Santa Susana; Monia Marchetti; Gabriele Magliano; Iker Falces-Romero; Osman Ilhan; Emanuele Ammatuna; Sofia Zompi; Panagiotis Tsirigotis; Anastasia Antoniadou; Giovanni Paolo Maria Zambrotta; Anna Nordlander; Linda Katharina Karlsson; Michaela Hanakova; Giulia Dragonetti; Alba Cabirta; Caroline Berg Venemyr; Stefanie Gräfe; Jens Van Praet; Athanasios Tragiannidis; Verena Petzer; Alberto López-García; Federico Itri; Ana Groh; Eleni Gavriilaki; Michelina Dargenio; Laman Rahimli; Oliver A. Cornely; Livio Pagano

doi:10.3389/fimmu.2023.1125030

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Alessandro Busca, Jon Salmanton-García, Francesco Marchesi, Francesca Farina, Guldane Cengiz Seval, Jaap Van Doesum, Nick De Jonge, Nathan C. Bahr, Johan Maertens, Joseph Meletiadis, Nicola S. Fracchiolla, Barbora Weinbergerová, Luisa Verga, Zdeněk Ráčil, Moraima Jiménez, Andreas Glenthøj, Ola Blennow, Alina Daniela Tanase, Martin Schönlein, Lucia PreziosoNina Khanna, Rafael F. Duarte, Pavel Žák, Marcio Nucci, Marina Machado, Austin Kulasekararaj, Ildefonso Espigado, Elizabeth De Kort, José-María Ribera-Santa Susana, Monia Marchetti, Gabriele Magliano, Iker Falces-Romero, Osman Ilhan, Emanuele Ammatuna, Sofia Zompi, Panagiotis Tsirigotis, Anastasia Antoniadou, Giovanni Paolo Maria Zambrotta, Anna Nordlander, Linda Katharina Karlsson, Michaela Hanakova, Giulia Dragonetti, Alba Cabirta, Caroline Berg Venemyr, Stefanie Gräfe, Jens Van Praet, Athanasios Tragiannidis, Verena Petzer, Alberto López-García, Federico Itri, Ana Groh, Eleni Gavriilaki, Michelina Dargenio, Laman Rahimli, Oliver A. Cornely, Livio Pagano

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.

Lingua originale	English
pagine (da-a)	1125030-1125037
Numero di pagine	8
Rivista	Frontiers in Immunology
Volume	14
DOI	https://doi.org/10.3389/fimmu.2023.1125030
Stato di pubblicazione	Pubblicato - 2023

Keywords

allogeneic HSCT
COVID-19 infection
SARS-CoV-2
immunocompromised patients
hematological malignances

Accesso al documento

10.3389/fimmu.2023.1125030

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Busca, A., Salmanton-García, J., Marchesi, F., Farina, F., Seval, G. C., Van Doesum, J., De Jonge, N., Bahr, N. C., Maertens, J., Meletiadis, J., Fracchiolla, N. S., Weinbergerová, B., Verga, L., Ráčil, Z., Jiménez, M., Glenthøj, A., Blennow, O., Tanase, A. D., Schönlein, M., ... Pagano, L. (2023). Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry. Frontiers in Immunology, 14, 1125030-1125037. https://doi.org/10.3389/fimmu.2023.1125030

@article{e2b8d5bcceb041c6941a2ca0ee4fb589,

title = "Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry",

abstract = "Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.",

keywords = "allogeneic HSCT, COVID-19 infection, SARS-CoV-2, immunocompromised patients, hematological malignances, allogeneic HSCT, COVID-19 infection, SARS-CoV-2, immunocompromised patients, hematological malignances",

author = "Alessandro Busca and Jon Salmanton-Garc{\'i}a and Francesco Marchesi and Francesca Farina and Seval, {Guldane Cengiz} and {Van Doesum}, Jaap and {De Jonge}, Nick and Bahr, {Nathan C.} and Johan Maertens and Joseph Meletiadis and Fracchiolla, {Nicola S.} and Barbora Weinbergerov{\'a} and Luisa Verga and Zden{\v e}k R{\'a}{\v c}il and Moraima Jim{\'e}nez and Andreas Glenth{\o}j and Ola Blennow and Tanase, {Alina Daniela} and Martin Sch{\"o}nlein and Lucia Prezioso and Nina Khanna and Duarte, {Rafael F.} and Pavel {\v Z}{\'a}k and Marcio Nucci and Marina Machado and Austin Kulasekararaj and Ildefonso Espigado and {De Kort}, Elizabeth and {Ribera-Santa Susana}, Jos{\'e}-Mar{\'i}a and Monia Marchetti and Gabriele Magliano and Iker Falces-Romero and Osman Ilhan and Emanuele Ammatuna and Sofia Zompi and Panagiotis Tsirigotis and Anastasia Antoniadou and Zambrotta, {Giovanni Paolo Maria} and Anna Nordlander and Karlsson, {Linda Katharina} and Michaela Hanakova and Giulia Dragonetti and Alba Cabirta and {Berg Venemyr}, Caroline and Stefanie Gr{\"a}fe and {Van Praet}, Jens and Athanasios Tragiannidis and Verena Petzer and Alberto L{\'o}pez-Garc{\'i}a and Federico Itri and Ana Groh and Eleni Gavriilaki and Michelina Dargenio and Laman Rahimli and Cornely, {Oliver A.} and Livio Pagano",

year = "2023",

doi = "10.3389/fimmu.2023.1125030",

language = "English",

volume = "14",

pages = "1125030--1125037",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

}

Busca, A, Salmanton-García, J, Marchesi, F, Farina, F, Seval, GC, Van Doesum, J, De Jonge, N, Bahr, NC, Maertens, J, Meletiadis, J, Fracchiolla, NS, Weinbergerová, B, Verga, L, Ráčil, Z, Jiménez, M, Glenthøj, A, Blennow, O, Tanase, AD, Schönlein, M, Prezioso, L, Khanna, N, Duarte, RF, Žák, P, Nucci, M, Machado, M, Kulasekararaj, A, Espigado, I, De Kort, E, Ribera-Santa Susana, J-M, Marchetti, M, Magliano, G, Falces-Romero, I, Ilhan, O, Ammatuna, E, Zompi, S, Tsirigotis, P, Antoniadou, A, Zambrotta, GPM, Nordlander, A, Karlsson, LK, Hanakova, M, Dragonetti, G, Cabirta, A, Berg Venemyr, C, Gräfe, S, Van Praet, J, Tragiannidis, A, Petzer, V, López-García, A, Itri, F, Groh, A, Gavriilaki, E, Dargenio, M, Rahimli, L, Cornely, OA & Pagano, L 2023, 'Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry', Frontiers in Immunology, vol. 14, pagg. 1125030-1125037. https://doi.org/10.3389/fimmu.2023.1125030

TY - JOUR

T1 - Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

AU - Busca, Alessandro

AU - Salmanton-García, Jon

AU - Marchesi, Francesco

AU - Farina, Francesca

AU - Seval, Guldane Cengiz

AU - Van Doesum, Jaap

AU - De Jonge, Nick

AU - Bahr, Nathan C.

AU - Maertens, Johan

AU - Meletiadis, Joseph

AU - Fracchiolla, Nicola S.

AU - Weinbergerová, Barbora

AU - Verga, Luisa

AU - Ráčil, Zdeněk

AU - Jiménez, Moraima

AU - Glenthøj, Andreas

AU - Blennow, Ola

AU - Tanase, Alina Daniela

AU - Schönlein, Martin

AU - Prezioso, Lucia

AU - Khanna, Nina

AU - Duarte, Rafael F.

AU - Žák, Pavel

AU - Nucci, Marcio

AU - Machado, Marina

AU - Kulasekararaj, Austin

AU - Espigado, Ildefonso

AU - De Kort, Elizabeth

AU - Ribera-Santa Susana, José-María

AU - Marchetti, Monia

AU - Magliano, Gabriele

AU - Falces-Romero, Iker

AU - Ilhan, Osman

AU - Ammatuna, Emanuele

AU - Zompi, Sofia

AU - Tsirigotis, Panagiotis

AU - Antoniadou, Anastasia

AU - Zambrotta, Giovanni Paolo Maria

AU - Nordlander, Anna

AU - Karlsson, Linda Katharina

AU - Hanakova, Michaela

AU - Dragonetti, Giulia

AU - Cabirta, Alba

AU - Berg Venemyr, Caroline

AU - Gräfe, Stefanie

AU - Van Praet, Jens

AU - Tragiannidis, Athanasios

AU - Petzer, Verena

AU - López-García, Alberto

AU - Itri, Federico

AU - Groh, Ana

AU - Gavriilaki, Eleni

AU - Dargenio, Michelina

AU - Rahimli, Laman

AU - Cornely, Oliver A.

AU - Pagano, Livio

PY - 2023

Y1 - 2023

N2 - Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.

AB - Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.

KW - allogeneic HSCT

KW - COVID-19 infection

KW - SARS-CoV-2

KW - immunocompromised patients

KW - hematological malignances

KW - allogeneic HSCT

KW - COVID-19 infection

KW - SARS-CoV-2

KW - immunocompromised patients

KW - hematological malignances

UR - http://hdl.handle.net/10807/235311

U2 - 10.3389/fimmu.2023.1125030

DO - 10.3389/fimmu.2023.1125030

M3 - Article

SN - 1664-3224

VL - 14

SP - 1125030

EP - 1125037

JO - Frontiers in Immunology

JF - Frontiers in Immunology

ER -

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo